The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: John Young - Canaccord Genuity - Analyst
: Thanks to this really informative presentation, I just want to start just, could you just talk about the feedback you've heard from the field since the
press release results were released. And then secondly, just, as we think about the cadence of the ramp, obviously, there's some, there's some
pretty big catalyst coming. We have a U A end of April and then obviously the reimbursement on 2026. But, can you talk about the revenue ramp
that you're expecting from prostate pacific? Thank you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
JANUARY 08, 2025 / 2:30PM, ANGO.OQ - AngioDynamics Inc To Host NanoKnife Investor Event
Question: John Young - Canaccord Genuity - Analyst
: And then just as a follow up, maybe, can you talk about just the economics of NITE versus other focal options and then just the other, options in
terms of like Raac will prospect to be in terms of incentives for positions. And then also we preserve the Preserve site itself, have any economic out
that we'll be seeing.
Question: Steve Lichtman - Oppenheimer - Analyst
: Thanks, James for a great presentation. I wanted to ask first on the direct to patient work. Can you talk a little bit more about what that looks like?
Is it all online or is there any commercial work? And I know it's early but any early comments you can make in terms of what you're seeing from
patients specifically as a result of those efforts.
Question: Steve Lichtman - Oppenheimer - Analyst
: Great, appreciate the update during the presentation the number of us facilities. I think you said it was about 100 and 20. Can you remind us of
what you see as sort of the denominator there? The opportunity for you guys over the medium to long-term and then maybe tie in with that your
capital outlook on the call. Earlier today. We talked about it being down year over year, I guess on, some tough comps. But how should we think
about the cadence of capital over the next number of quarters?
Question: Steve Lichtman - Oppenheimer - Analyst
: I just wanted to ask one last one on International Jake. You talk about some of the progress during your presentation. How big is international
today? And do you see that as a material driver on the next couple of years or, or will it be more us focused near term?
| 
